Wu Charles C 4
4 · GYRE THERAPEUTICS, INC. · Filed Nov 22, 2023
Insider Transaction Report
Form 4
Wu Charles C
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-11-20+170,417→ 170,417 totalExercise: $0.75Exp: 2030-10-31→ Common Stock (170,417 underlying)
Footnotes (2)
- [F1]Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
- [F2]These options are vested in full.